Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
54 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Paraganglioma (Glomus Jugulare Tumor) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Paraganglioma (Glomus Jugulare Tumor) - Pipeline Review, H2 2014', provides an overview of the Paraganglioma (Glomus Jugulare Tumor)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Paraganglioma (Glomus Jugulare Tumor), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Paraganglioma (Glomus Jugulare Tumor) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Paraganglioma (Glomus Jugulare Tumor) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Paraganglioma (Glomus Jugulare Tumor) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Paraganglioma (Glomus Jugulare Tumor) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Paraganglioma (Glomus Jugulare Tumor) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Paraganglioma (Glomus Jugulare Tumor) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Paraganglioma (Glomus Jugulare Tumor) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Paraganglioma (Glomus Jugulare Tumor) Overview 6 Therapeutics Development 7 Pipeline Products for Paraganglioma (Glomus Jugulare Tumor) - Overview 7 Pipeline Products for Paraganglioma (Glomus Jugulare Tumor) - Comparative Analysis 8 Paraganglioma (Glomus Jugulare Tumor) - Therapeutics under Development by Companies 9 Paraganglioma (Glomus Jugulare Tumor) - Pipeline Products Glance 10 Clinical Stage Products 10 Paraganglioma (Glomus Jugulare Tumor) - Products under Development by Companies 11 Paraganglioma (Glomus Jugulare Tumor) - Companies Involved in Therapeutics Development 12 AstraZeneca PLC 12 Novartis AG 13 Pfizer Inc. 14 Progenics Pharmaceuticals, Inc. 15 Paraganglioma (Glomus Jugulare Tumor) - Therapeutics Assessment 16 Assessment by Monotherapy Products 16 Assessment by Target 17 Assessment by Mechanism of Action 19 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Drug Profiles 24 dovitinib lactate - Drug Profile 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 everolimus - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 iobenguane sulfate I 131 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 sunitinib malate - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 vandetanib - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Paraganglioma (Glomus Jugulare Tumor) - Recent Pipeline Updates 45 Appendix 53 Methodology 53 Coverage 53 Secondary Research 53 Primary Research 53 Expert Panel Validation 53 Contact Us 54 Disclaimer 54
List of Tables Number of Products under Development for Paraganglioma (Glomus Jugulare Tumor), H2 2014 7 Number of Products under Development for Paraganglioma (Glomus Jugulare Tumor) - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Comparative Analysis by Clinical Stage Development, H2 2014 10 Products under Development by Companies, H2 2014 11 Paraganglioma (Glomus Jugulare Tumor) - Pipeline by AstraZeneca PLC, H2 2014 12 Paraganglioma (Glomus Jugulare Tumor) - Pipeline by Novartis AG, H2 2014 13 Paraganglioma (Glomus Jugulare Tumor) - Pipeline by Pfizer Inc., H2 2014 14 Paraganglioma (Glomus Jugulare Tumor) - Pipeline by Progenics Pharmaceuticals, Inc., H2 2014 15 Assessment by Monotherapy Products, H2 2014 16 Number of Products by Stage and Target, H2 2014 18 Number of Products by Stage and Mechanism of Action, H2 2014 20 Number of Products by Stage and Route of Administration, H2 2014 22 Number of Products by Stage and Molecule Type, H2 2014 23 Paraganglioma (Glomus Jugulare Tumor) Therapeutics - Recent Pipeline Updates, H2 2014 45
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.